NCT03547115View on ClinicalTrials.gov

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

PHASE1UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 31, 2018

Primary Completion Date

April 30, 2024

Study Completion Date

March 31, 2025

Conditions
Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)Small Lymphocytic Lymphoma (SLL)Chronic Lymphocytic Leukemia (CLL)Diffuse Large B-cell Lymphoma (DLBCL)Acute Myeloid Leukemia (AML)
Interventions
DRUG

voruciclib monotherapy

Voruciclib will be administered orally

DRUG

voruciclib and venetoclax

Voruciclib and Venetoclax will be administered orally

Trial Locations (12)

10016

ACTIVE_NOT_RECRUITING

New York University, New York

22903

RECRUITING

University of Virginia, Charlottesville

27705

ACTIVE_NOT_RECRUITING

Duke University, Durham

53226

RECRUITING

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee

55905

RECRUITING

Mayo Clinic, Rochester

60611

RECRUITING

Northwestern Memorial Hospital, Chicago

68198

RECRUITING

University of Nebraska Medical Center, Omaha

77030

RECRUITING

MD Anderson, Houston

91010

RECRUITING

City of Hope, Duarte

97239

RECRUITING

Oregon Health and Science University, Portland

98104

ACTIVE_NOT_RECRUITING

Swedish Cancer Institute, Seattle

02215

ACTIVE_NOT_RECRUITING

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

MEI Pharma, Inc.
All Listed Sponsors
lead

MEI Pharma, Inc.

INDUSTRY

NCT03547115 - A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML | Biotech Hunter | Biotech Hunter